Published: Jan 06, 2021 By Mark Terry
SARS-CoV-2, the virus that causes COVID-19, has mutated into several strains. Most of them are not particularly different than the primary strains, but two, B.1.1.7, which was first observed in the U.K., and now 501.V2, which originated in South Africa, have virologists
watching closely. Although neither strain appears to be more deadly or to cause more severe illness than earlier strains, both appear to be more transmissible, or “catchy.”
The South African variant has been identified in the U.K., Switzerland, Finland, Japan, Australia, Zambia, France and South Korea, so far. Anthony Fauci, director of the U.S. National Institute of Allergy and Infectious Diseases (NIAID), said, “I would be surprised if it were not already in the United States, but you never know until you find it, and then prove it’s here. But thus far, we have not detected the South African strain.”
Donald Trump Launches Office Of The Former President To Carry On Agenda
Donald Trump released a statement on Monday announcing the launch of the Office of the Former President, as reported by
Business Insider. The office will be based out of Palm Beach County, Florida, also home to the Mar-a-Lago resort he currently resides at following his exit from the White House prior to Joe Biden s inauguration on January 20. The office will manage Trump s affairs in relation to continuing the goals of his administration. The office will be responsible for managing President Trump s correspondences, public statements, appearances, and official activities to advance the interests of the United States and to carry on the agenda of the Trump Administration through advocacy, organizing, and public activism, the statement read.
Analysis Demonstrates Effectiveness of LY-CoV555 Antibody in Preventing Symptomatic COVID-19
Analysis Demonstrates Effectiveness of LY-CoV555 Antibody in Preventing Symptomatic COVID-19
DURHAM, N.C., Jan. 25, 2021 Researchers from the COVID-19 Prevention Network (CoVPN) announced that the monoclonal antibody (mAb), LY-CoV555 (bamlanivimab), evaluated in a Phase III trial significantly reduces the risk of contracting symptomatic COVID-19 as well as reduces the clinical course of COVID-19 in study participants who did become symptomatic. The study, CoVPN 3501, was conducted in collaboration with Eli Lilly and Company in skilled nursing facilities (SNFs) across the United States. Residents and staff at SNFs participated in the trial.
A total of 1,097 participants (340 residents, 757 staff) were randomized to receive either a single 4,200 mg dose of LY-CoV555 or placebo (saline). Half of the study participants received LY-CoV555 and h
Virus Outbreak: Biden orders more travel restrictions, adds S Africa taipeitimes.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from taipeitimes.com Daily Mail and Mail on Sunday newspapers.